| From : | Tamar Gabunia </O=EXCHORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=E6CA04F38EC94D0CADAB9CBDF90FCDDE-TAMAR G> |
| To : | MAMULASHVILI; Nino <mamulashvilin@who.int>; Anzor tchavtchavadze </o=ExchOrganization/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0e03f3df18104f3b8b06b0400c558fbf-Anzor t>; tt@aidscenter.ge |
| Subject : | Re: Questions related to country inclusion in Solidarity Trial |
| Cc : | Ekaterine Adamia </o=ExchOrganization/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89b4d31758d34f2cbdcfe688199f6941-Ekateri>; DOMENTE; Silviu <domentes@who.int> |
| Received On : | 07.04.2020 03:47 |
Dear Nino
Many thanks for facilitating this process. It is really important for us to join the Solidarity trial initiative. Hopefully inclusion process will go smoothly.
Best
Tamar
Dear Colleagues,
Please find enclosed some clarifications provided from Masoud Dara on response to two questions raised during today Clinical Advisory Group meeting at the MoH.
Kind regards, Nino
From: DARA, Masoud
Sent: Monday, April 6, 2020 21:16
To: MAMULASHVILI, Nino
Cc: LYDON, Patrick
Subject: RE: Questions related to country inclusion in Solidarity Trial
Dear Nino,
Thank you for discussing Solidarity with MoH and the national experts. We are planning to organize an additional session for EURO countries, which we could also discuss the details with them.
Please find response below:
Thanks and regards,
Masoud
From: MAMULASHVILI, Nino <mamulashvilin@who.int>
Sent: Monday, April 6, 2020 4:58 PM
To: DARA, Masoud <daram@who.int>
Cc: LYDON, Patrick <lydonp@who.int>; DOMENTE, Silviu <domentes@who.int>
Subject: Questions related to country inclusion in Solidarity Trial
Importance: High
Dear Masoud,
Please be informed that today I was asked by the Deputy Minister, Tamar Gabunia, to join the video call during the Clinical Advisory Group meeting that took place at the Ministry.
I have provided information on Solidarity Trial details, followed by questions from the Group members.
I am forwarding you two questions we would like to have WHO clarification on:
MD: As elaborated in the study protocol, it will be 1:1:1:1:1 randomization, this is to increase the credibility of the findings (randomized Clinical Trial). The randomization will happen automatically for all eligible patients based on the mentioned criteria. We propose to have all four arms compared to the standard of care, however should there be concerns or suggestions, we could discuss them with the MoH and appointed principal investigator(s).
MD: Medicine will be provided based on the country needs. If Kaletra or other medicines with quality assurance would be available in the country, we would not need to arrange their shipment to Georgia.
Looking forward to hearing soon from you.
Kind regards, Nino
__________________________________
Dr. Nino Mamulashvili
Program Coordinator
WHO Country Office Georgia
Office location: 81 Vasil Barnov Street, 0179 Tbilisi, Georgia
Mailing address: UN House, 9 Rapiel Eristavi Street, 0179 Tbilisi, Georgia
Mobile: +995 599 567 244
E-mail: mamulashvilin@who.int
GPN: 74212